New JNNP study: In aggressive #RRMS, AHSCT greatly reduced PIRA: 10% over 10 years vs 49% in patients moving from natalizumab to other DMTs. Findings suggest #AHSCT may target the silent, smoldering processes that drive MS progression.
🟢More on AHSCT and MS at curems.net

🎉 curems.net turns one!
In 12 months:
🟢 40% Italian, 60% international readers
🟢 1,250+ contacts from 56 countries
🟢 152 scientific papers cited
🟢 Biweekly updates
CureMS.net is becoming a key resource on #AHSCT for patients and professionals. Thanks to all who support and to all the readers! #MS

Kalincik et al. ( #ECTRIMS 2025) compared #AHSCT (152 pts) vs anti-CD20 (Ocrelizumab 752, Rituximab 107).
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...

Boffa & Genchi et al. review on aggressive #MultipleSclerosis (EBMT registry, 2,200 pwMS): #AHSCT should be considered early in poor prognosis cases, including DMT non-responders & treatment-naïve with rapid progression.
🟢 More info: journals.sagepub.com/doi/10.1177/...
🔵 Visit curems.net

🔵 Two studies used CyTOF to map immune reconstitution post-AHSCT in MS: Gavasso et al. found CD4⁺ memory T cell loss and naïve B cell expansion; Müller et al. reported Th1/Th17, MAIT cell decline, and relapse link to IgD⁺IgM⁺ B cells.
🟢 More info: curems.net/benefits-of-...

The ECTRIMS/EBMT consensus (www.nature.com/articles/s41...) states AHSCT should be offered to RRMS patients unresponsive to HE-DMTs. Neurologists and patients must weigh AHSCT’s unique long-term benefits—over 50% achieve NEDA-3 for 10+ years without further therapy. See curems.net/benefits-of-...

CureMS.net screened PubMed and Google Scholar, reviewing 21 studies on RRMS patients treated with AHSCT (intermediate conditioning, 1–10 years follow-up). At 10 years, 40–78% maintained NEDA-3; BEAM+ATG studies reported 55–78%. Total patients: 1145 (possible duplicates). curems.net/benefits-of-...

Although AHSCT (autologous hematopoietic stem cell transplantation) is a treatment option for some pwMS, this option is not always communicated to them.
Here are some personal reflections on the doctor-patient relationship.
More info at curems.net
Read the new section here lnkd.in/dyhgnUqP

Welcome to curems.net, an Evidence-based, nonprofit resource on Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for MS. 
🟢 Free, updated, downloadable materials on transplant.
🟢 Providing reliable information to guide patients and healthcare professionals.  
📌 Visit curems.net